40 results on '"Fujiwara, Y."'
Search Results
2. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
- Author
-
Yamamoto, H., primary, Ando, M., additional, Aogi, K., additional, Iwata, H., additional, Tamura, K., additional, Yonemori, K., additional, Shimizu, C., additional, Hara, F., additional, Takabatake, D., additional, Hattori, M., additional, Asakawa, T., additional, and Fujiwara, Y., additional
- Published
- 2014
- Full Text
- View/download PDF
3. Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases
- Author
-
Mizugaki, H., primary, Fujiwara, Y., additional, Yamamoto, N., additional, Yagishita, S., additional, Kitazono, S., additional, Tanaka, A., additional, Horinouchi, H., additional, Kanda, S., additional, Nokihara, H., additional, Tsuta, K., additional, Asamura, H., additional, and Tamura, T., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Secondary Osteosarcoma Developing 10 Years after Chemoradiotherapy for Non-small-cell Lung Cancer
- Author
-
Yagishita, S., primary, Horinouchi, H., additional, Yorozu, T., additional, Kitazono, S., additional, Mizugaki, H., additional, Kanda, S., additional, Fujiwara, Y., additional, Nokihara, H., additional, Yamamoto, N., additional, Mori, T., additional, Tsuta, K., additional, Sumi, M., additional, and Tamura, T., additional
- Published
- 2013
- Full Text
- View/download PDF
5. Prediction of Glomerular Filtration Rate in Cancer Patients by an Equation for Japanese Estimated Glomerular Filtration Rate
- Author
-
Funakoshi, Y., primary, Fujiwara, Y., additional, Kiyota, N., additional, Mukohara, T., additional, Shimada, T., additional, Toyoda, M., additional, Imamura, Y., additional, Chayahara, N., additional, Umezu, M., additional, Otsuki, N., additional, Nibu, K.-i., additional, and Minami, H., additional
- Published
- 2013
- Full Text
- View/download PDF
6. Prognostic Factors in Young Japanese Women with Breast Cancer: Prognostic Value of Age at Diagnosis
- Author
-
Yoshida, M., primary, Shimizu, C., additional, Fukutomi, T., additional, Tsuda, H., additional, Kinoshita, T., additional, Akashi-Tanaka, S., additional, Ando, M., additional, Hojo, T., additional, and Fujiwara, Y., additional
- Published
- 2010
- Full Text
- View/download PDF
7. De-identification Procedure and Sample Quality of the Post-clinical Test Samples at the Bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo
- Author
-
Furuta, K., primary, Yokozawa, K., additional, Takada, T., additional, and Fujiwara, Y., additional
- Published
- 2010
- Full Text
- View/download PDF
8. Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment
- Author
-
Suzuki, Y., primary, Tokuda, Y., additional, Fujiwara, Y., additional, Iwata, H., additional, Sasaki, Y., additional, Saji, S., additional, Aogi, K., additional, Nambu, Y., additional, Suri, A., additional, Saeki, T., additional, and Takashima, S., additional
- Published
- 2009
- Full Text
- View/download PDF
9. Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer
- Author
-
Shimizu, C., primary, Masuda, N., additional, Yoshimura, K., additional, Tsuda, H., additional, Mano, M., additional, Ando, M., additional, Tamura, K., additional, and Fujiwara, Y., additional
- Published
- 2009
- Full Text
- View/download PDF
10. Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial
- Author
-
Yonemura, M., primary, Katsumata, N., additional, Hashimoto, H., additional, Satake, S., additional, Kaneko, M., additional, Kobayashi, Y., additional, Takashima, A., additional, Kato, Y., additional, Takeuchi, M., additional, Fujiwara, Y., additional, Yamamoto, H., additional, and Hojo, T., additional
- Published
- 2009
- Full Text
- View/download PDF
11. Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
- Author
-
Yamamoto, N., primary, Yamada, Y., additional, Fujiwara, Y., additional, Yamada, K., additional, Fujisaka, Y., additional, Shimizu, T., additional, and Tamura, T., additional
- Published
- 2009
- Full Text
- View/download PDF
12. Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group
- Author
-
Katsumata, N., primary, Fujiwara, Y., additional, Kamura, T., additional, Nakanishi, T., additional, Hatae, M., additional, Aoki, D., additional, Tanaka, K., additional, Tsuda, H., additional, Kamiura, S., additional, Takehara, K., additional, Sugiyama, T., additional, Kigawa, J., additional, Fujiwara, K., additional, Ochiai, K., additional, Ishida, R., additional, Inagaki, M., additional, and Noda, K., additional
- Published
- 2008
- Full Text
- View/download PDF
13. Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer
- Author
-
Ono, M., primary, Watanabe, T., additional, Shimizu, C., additional, Hiramoto, N., additional, Goto, Y., additional, Yonemori, K., additional, Kouno, T., additional, Ando, M., additional, Tamura, K., additional, Katsumata, N., additional, and Fujiwara, Y., additional
- Published
- 2008
- Full Text
- View/download PDF
14. Clinical Efficacy of S-1 in Pretreated Metastatic Breast Cancer Patients
- Author
-
Shien, T., primary, Shimizu, C., additional, Akashi-Tanaka, S., additional, Yonemori, K., additional, Kohno, T., additional, Hojo, T., additional, Ando, M., additional, Katsumata, N., additional, Kinoshita, T., additional, and Fujiwara, Y., additional
- Published
- 2008
- Full Text
- View/download PDF
15. Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy
- Author
-
Suzuki, Y., primary, Tokuda, Y., additional, Fujiwara, Y., additional, Minami, H., additional, Ohashi, Y., additional, and Saijo, N., additional
- Published
- 2008
- Full Text
- View/download PDF
16. Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung
- Author
-
Fujiwara, Y., primary, Sekine, I., additional, Tsuta, K., additional, Ohe, Y., additional, Kunitoh, H., additional, Yamamoto, N., additional, Nokihara, H., additional, Yamada, K., additional, and Tamura, T., additional
- Published
- 2007
- Full Text
- View/download PDF
17. Homepage of the Month
- Author
-
Fujiwara, Y., primary
- Published
- 2005
- Full Text
- View/download PDF
18. MD Reviewers' Role in the New Anticancer Drug Approval Process in the Newly Established Japanese Regulatory Agency, PMDEC (Pharmaceuticals and Medical Devices Evaluation Center)
- Author
-
Fujiwara, Y., primary
- Published
- 1998
- Full Text
- View/download PDF
19. Suppressed Apoptotic Induction in Esophageal Squamous Cell Carcinomas Expressing Extensive p53 Protein
- Author
-
Hamada, M., primary, Fujiwara, Y. N. T., additional, Kamikawa, Y., additional, and Noriaki, T., additional
- Published
- 1996
- Full Text
- View/download PDF
20. Phase II Study of Carboplatin in Small Cell Lung Cancer
- Author
-
Tamura, T., primary, Saijo, N., additional, Shinkai, T., additional, Eguchi, K., additional, Sasaki, Y., additional, Sakurai, M., additional, Fujiwara, Y., additional, Nakano, H., additional, Nakagawa, K., additional, Minato, K., additional, and Hong, W.-S., additional
- Published
- 1988
- Full Text
- View/download PDF
21. Current diagnosis and treatment of salivary gland-type tumors of the lung.
- Author
-
Horio Y, Kuroda H, Masago K, Matsushita H, Sasaki E, and Fujiwara Y
- Subjects
- Humans, Salivary Glands metabolism, Salivary Glands pathology, Carcinoma, Adenoid Cystic diagnosis, Carcinoma, Adenoid Cystic genetics, Carcinoma, Adenoid Cystic therapy, Carcinoma, Mucoepidermoid diagnosis, Carcinoma, Mucoepidermoid genetics, Carcinoma, Mucoepidermoid therapy, Salivary Gland Neoplasms diagnosis, Salivary Gland Neoplasms genetics, Salivary Gland Neoplasms therapy, Carcinoma pathology, Myoepithelioma pathology, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Lung Neoplasms therapy
- Abstract
Salivary gland-type tumors of the lung are thought to originate from the submucosal exocrine glands of the large airways. Due to their rare occurrence, reports of their study are limited to small-scale or case reports. Therefore, daily clinical practices often require a search for previous reports. In the last 20 years, several genetic rearrangements have been identified, such as MYB::NF1B rearrangements in adenoid cystic carcinoma, CRTC1::MAML2 rearrangements in mucoepidermoid carcinoma, EWSR1::ATF1 rearrangements in hyalinizing clear cell carcinoma and rearrangements of the EWSR1 locus or FUS (TLS) locus in myoepithelioma and myoepithelial carcinoma. These molecular alterations have been useful in diagnosing these tumors, although they have not yet been linked to molecularly targeted therapies. The morphologic, immunophenotypic, and molecular characteristics of these tumors are similar to those of their counterparts of extrapulmonary origin, so clinical and radiologic differential diagnosis is required to distinguish between primary and metastatic disease of other primary sites. However, these molecular alterations can be useful in differentiating them from other primary lung cancer histologic types. The management of these tumors requires broad knowledge of the latest diagnostics, surgery, radiotherapy, bronchoscopic interventions, chemotherapy, immunotherapy as well as therapeutic agents in development, including molecularly targeted agents. This review provides a comprehensive overview of the current diagnosis and treatment of pulmonary salivary gland tumors, with a focus on adenoid cystic carcinoma and mucoepidermoid carcinoma, which are the two most common subtypes., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
22. A new era of the Asian clinical research network: a report from the ATLAS international symposium.
- Author
-
Terada M, Nakamura K, Matsuda T, Okuma HS, Sudo K, Yusof A, Imasa M, Sirachainan E, Anh PT, Fujiwara Y, Yamamoto N, Voon PJ, Chokephaibulkit K, Shibata T, Inoue M, Mano H, Shimoi T, Sriuranpong V, Yonemori K, and Shimada K
- Subjects
- Humans, Thailand, Japan, Medical Oncology, Neoplasms genetics, Neoplasms therapy
- Abstract
This report summarizes the presentations and discussions in the first Asian Clinical Trials Network for Cancers (ATLAS) international symposium that was held on 24 April 2022, in Bangkok, Thailand, and hosted by the National Cancer Center Hospital (NCCH), co-hosted by the Pharmaceuticals and Medical Devices Agency (PMDA), Clinical Research Malaysia (CRM) and the Thai Society of Clinical Oncology (TSCO), and supported by Embassy of Japan in Thailand. Since 2020, the NCCH has conducted the ATLAS project to enhance research environments and infrastructures to facilitate international clinical research and cancer genomic medicine in the Asian region. The purpose of the symposium was to discuss what we can achieve under the ATLAS project, to share the latest topics and common issues in cancer research and to facilitate mutual understanding. Invitees included stakeholders from academic institutions, mainly at ATLAS collaborative sites, as well as Asian regulatory authorities. The invited speakers discussed ongoing collaborative research, regulatory perspectives to improve new drug access in Asia, the status of phase I trials in Asia, the introduction of research activities at the National Cancer Center (NCC) and the implementation of genomic medicine. As the next steps after this symposium, the ATLAS project will foster increased cooperation between investigators, regulatory authorities and other stakeholders relevant to cancer research, and establish a sustainable pan-Asian cancer research group to increase the number of clinical trials and deliver novel drugs to patients with cancer in Asia., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
23. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
- Author
-
Naito T, Shiraishi H, and Fujiwara Y
- Subjects
- Aminopyridines, Anaplastic Lymphoma Kinase analysis, Carcinoma, Non-Small-Cell Lung enzymology, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Crizotinib therapeutic use, Drug Resistance, Neoplasm genetics, Humans, Lactams, Lung Neoplasms enzymology, Lung Neoplasms mortality, Lung Neoplasms pathology, Pyrazoles, Anaplastic Lymphoma Kinase antagonists & inhibitors, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Central Nervous System Neoplasms secondary, Lactams, Macrocyclic therapeutic use, Lung Neoplasms drug therapy, Mutation, Organophosphorus Compounds therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
- Abstract
Major issues in anaplastic lymphoma kinase-positive non-small cell lung carcinoma are acquired resistance against anaplastic lymphoma kinase inhibitors and control of central nervous system metastasis. The development of these inhibitors has changed therapeutic strategy in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung carcinoma. Brigatinib and lorlatinib were designed to penetrate the blood-brain barrier and to inhibit resistant mutations against anaplastic lymphoma kinase inhibitors. We review the clinical data supporting treatment of advanced anaplastic lymphoma kinase-positive non-small cell lung carcinoma with brigatinib and lorlatinib. Brigatinib has shown promising antitumour activity, including substantial activity against central nervous system metastases, in crizotinib-treated (ALTA trial) patients and crizotinib-naïve (ALTA-1L trial) patients with anaplastic lymphoma kinase-positive non-small cell lung carcinoma. In addition, brigatinib improved progression-free survival compared with crizotinib in anaplastic lymphoma kinase inhibitor-naïve patients with anaplastic lymphoma kinase-positive non-small cell lung carcinoma. Lorlatinib has demonstrated clinical antitumour activity against both intracranial and extracranial lesions in patients with anaplastic lymphoma kinase- or c-ros oncogene 1 (ROS1)-positive non-small cell lung carcinoma. Ongoing trials and further studies of these agents' biological and clinical properties would provide insight into the optimal therapeutic strategy for administering them to achieve the best survival benefit., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
24. Rare cancers in Japan: definition, clinical features and future perspectives.
- Author
-
Kawai A, Higashi T, Shibata T, Yoshida A, Katoh Y, Fujiwara Y, and Nishida T
- Subjects
- Humans, Japan, Neoplasms epidemiology, Rare Diseases epidemiology
- Abstract
This review introduces the definition, epidemiology and therapeutic challenges of rare cancers and describes the establishment of the Rare Cancer Center at the National Cancer Center, Japan. Rare cancers are defined as malignant tumors with an incidence rate of less than 6 cases per 100 000 individuals. Due to their low incidence rate, medical treatment for rare cancers is more challenging than for more common cancer types. Specifically, 190 types of cancers, including bone and soft tissue sarcomas, gastrointestinal stromal tumors (GISTs), neuroendocrine tumors and gliomas, are classified as rare cancers. Individually, each of the rare cancers accounts for less than 1% of all cancers, but collectively they account for 15% of all cancers. On the basis of their medical management, rare cancers can be subclassified into two types: Type I (rare cancers within cancer-rare organs) and Type II (rare cancers within cancer-common organs). Most importantly, the outcomes for rare cancers are poorer compared to those of common cancers. In 2014, the Rare Cancer Center was established at the National Cancer Center to address the various challenges related to rare cancers. The Rare Cancer Center has adopted a multifaceted approach for overcoming these challenges, including active sharing of information through a dedicated website and an online seminar series 'Rare Cancer Meet the Expert', providing medical support through telephone consultations via a 'Rare Cancer Hotline', supporting basic research and establishing the 'MASTER KEY Project' aimed at developing new treatments., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
25. Expectations of and recommendations for a cancer survivorship guideline in Japan: a literature review of guidelines for cancer survivorship.
- Author
-
Okubo R, Wada S, Shimizu Y, Tsuji K, Hanai A, Imai K, Uchitomi Y, Fujiwara Y, Tsugane S, and Matsuoka YJ
- Subjects
- Antineoplastic Agents adverse effects, Cardiovascular Diseases chemically induced, Cardiovascular Diseases etiology, Cognitive Dysfunction etiology, Fatigue chemically induced, Fatigue etiology, Female, Humans, Japan, Language, Male, Neoplasm Recurrence, Local diagnosis, Neoplasms complications, Neoplasms psychology, Neoplasms therapy, Neoplasms, Second Primary diagnosis, Pain etiology, Sexual Dysfunction, Physiological etiology, Sleep Wake Disorders etiology, Stress, Psychological etiology, Cancer Survivors psychology, Neoplasms pathology, Practice Guidelines as Topic
- Abstract
Background: Optimal cancer survivorship care needs its comprehensive guidelines. We aimed to identify English and Japanese guidelines that include cancer survivorship in their title, the issues highlighted in such guidelines, and any existing oncology practice guidelines in Japan that address these issues., Methods: This literature review was performed in three stages. First, guidelines published in English or Japanese that included cancer survivorship in the title were identified. Then, the issues that each cancer survivorship guideline addressed were defined. Lastly, Japanese guidelines that include survivorship issues were sought., Results: Six guidelines published in English addressed 31 cancer survivorship issues. No specific cancer survivorship guideline was available in Japanese. Thirty-four Japanese guidelines mentioned cancer survivorship issues. These guidelines addressed screening/surveillance for detecting recurrence or secondary cancer but did not address coordination of care, implications for practice, or inclusion of family. At present, Japanese guidelines poorly address the issue of promotion of a healthy lifestyle in cancer survivors. Also, poorly addressed were long-term and late effects such as pain, psychological distress, fatigue, cognitive dysfunction, cardiovascular effects (including anthracycline-induced cardiac toxicity), sleep disorders, and sexual dysfunction in cancer survivors., Conclusion: There is a need for guidelines on optimal coordination of care between oncologists and other health care providers to support patients along the cancer care continuum and specifically to encourage a healthy lifestyle as part of cancer survivorship. The development of a comprehensive Japanese guideline that addresses these issues would help to improve the clinical outcome for cancer survivors in Japan., (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
26. Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions.
- Author
-
Ohara S, Kanda S, Okuma H, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Ito Y, Yamamoto N, Usui K, Homma S, and Ohe Y
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Japan, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Retrospective Studies, Treatment Outcome, Young Adult, Chemoradiotherapy adverse effects, Lung Neoplasms therapy, Small Cell Lung Carcinoma therapy
- Abstract
Background: The standard treatment for limited-disease small-cell lung cancer (LD-SCLC) is a combination of chemotherapy and concurrent thoracic radiotherapy. In selected cases, sequential radiotherapy is preferred because of the need for a large irradiation field, patient age, comorbidities or performance status. Nevertheless, the efficacy of sequential chemoradiotherapy in patients in whom concurrent chemoradiotherapy is contraindicated is not well known., Methods: We retrospectively analyzed 286 patients with LD-SCLC at two institutions in Japan between 2000 and 2014. We compared the clinical characteristics and treatment outcomes of patients undergoing sequential radiotherapy with those undergoing concurrent radiotherapy., Results: One hundred and seventy-five patients received concurrent chemoradiotherapy, 33 received sequential chemoradiotherapy and 46 received chemotherapy only. The median patient age was 64 years (range, 18-82 years) for the concurrent group and 71 years (49-82 years) for the sequential group. Conventional radiotherapy was selected more frequently than accelerated hyperfractionated radiotherapy (27 patients [82%] with conventional radiotherapy, and six patients [18%] with hyperfractionated radiotherapy). The major reasons for the selection of sequential radiotherapy were advanced age (12 patients) and a large irradiation field (11 patients). The median overall survival time was 41.1 months for the sequential group and 38.1 months for the concurrent group. The 5-year survival rates were 36.0% for the sequential group and 41.6% for the concurrent group., Conclusions: In clinical situation, since the treatment outcomes for patients with sequential radiotherapy were comparable to those receiving concurrent radiotherapy, sequential chemoradiotherapy can be a choice for the treatment of patients who are not candidates for concurrent chemoradiotherapy., (© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2018
- Full Text
- View/download PDF
27. Efficacy and safety of osimertinib in a Japanese compassionate use program.
- Author
-
Fujiwara Y, Goto Y, Kanda S, Horinouchi H, Yamamoto N, Sakiyama N, Ando Makihara R, and Ohe Y
- Subjects
- Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Female, Humans, Japan, Lung Neoplasms pathology, Male, Middle Aged, Piperazines adverse effects, Protein Kinase Inhibitors adverse effects, Retrospective Studies, Survival Rate, Carcinoma, Non-Small-Cell Lung drug therapy, Compassionate Use Trials methods, Lung Neoplasms drug therapy, Piperazines administration & dosage, Protein Kinase Inhibitors administration & dosage
- Abstract
Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets the T790M mutation of EGFR. In 2016, AstraZeneca conducted a compassionate use program for osimertinib in Japan., Methods: Eighteen consecutive patients with histologically proven non-small-cell lung cancer (NSCLC) and harboring the T790M EGFR mutation participated in the compassionate use program between 1 April and 25 May 2016, at the National Cancer Center Hospital. We examined the efficacy and safety of osimertinib in a compassionate use program., Results: All patients had been previously treated with both cytotoxic chemotherapy and EGFR TKIs. Overall response rate was 62.5% (95% confidence interval (CI): 35.9-89.1%). Among the six patients pretreated with a third-generation EGFR TKI, two (33%) responded to osimertinib. On administration with osimertinib, median progression-free and overall survival rates at six months were 66.7% (95% CI: 44.9-88.5) and 88.9% (95% CI: 74.4-100), respectively. Although the toxicity of osimertinib was mild in most patients, three patients had severe adverse events: two developed interstitial lung disease (ILD) and one developed Grade 3 hepatotoxicity. Among these, two (33%) of the six patients who received osimertinib following nivolumab treatment developed severe adverse events, with one each developing Grade 3 hepatotoxicity and Grade 3 ILD. Only one patient visited our hospital seeking to participate in the compassionate program from another hospital., Conclusion: Osimertinib demonstrated efficacy even in patients with heavily pretreated NSCLC harboring the T790M mutation. Some patients pretreated with another third-generation EGFR TKI also responded to osimertinib., (© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com)
- Published
- 2017
- Full Text
- View/download PDF
28. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
- Author
-
Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, and Ohe Y
- Subjects
- Adult, Aged, Anthracyclines adverse effects, Antineoplastic Agents adverse effects, Disease-Free Survival, Female, Humans, Incidence, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neutropenia etiology, Pneumonia etiology, Survival Rate, Thrombocytopenia etiology, Young Adult, Anthracyclines therapeutic use, Antineoplastic Agents therapeutic use, Lung Neoplasms drug therapy, Small Cell Lung Carcinoma drug therapy
- Abstract
Objective: Most of the previous studies of amrubicin in patients with previously treated small-cell lung cancer were conducted at a dose of 40 mg/m(2). The aim of this study was to assess the efficacy and safety of amrubicin at a dose of 45 mg/m(2) in patients with relapsed or refractory small-cell lung cancer., Methods: Previously treated small-cell lung cancer patients were eligible. Amrubicin at a dose of 45 mg/m(2) was administered on Days 1-3 every 3 weeks. The primary endpoint was the response rate., Results: From June 2003 to January 2005, 35 patients were enrolled, of whom 34 received this study treatment. Four cycles or more could be administered in 21 patients (62%). Dose reduction was required in 15 (52%) of the 29 patients who had received two cycles or more. Three complete responses and 15 partial responses were observed among the 34 treated patients, yielding a response rate of 53% (95% confidence interval, 35-71%). Median progression-free survival of the patients was 4.4 months (95% confidence interval, 2.4-5.1 months). Median survival time was 8.2 months (95% confidence interval, 6.6-10.0 months) and 1-year survival rate was 24% (95% confidence interval, 9-39%). Grade 3/4 leukopenia, neutropenia and thrombocytopenia were observed in 76, 97 and 38% of the patients, respectively. Febrile neutropenia occurred in 12 patients (35%), and one patient died from pneumonia., Conclusions: While amrubicin at a dose of 45 mg/m(2) showed high response rate for both sensitive and refractory relapse, the incidence of febrile neutropenia was also high. The utility of amrubicin at 45 mg/m(2) might accordingly be limited., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
29. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
- Author
-
Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, Shimizu C, Hara F, Takabatake D, Hattori M, Asakawa T, and Fujiwara Y
- Subjects
- Ado-Trastuzumab Emtansine, Adult, Aged, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized blood, Antineoplastic Agents adverse effects, Antineoplastic Agents blood, Area Under Curve, Asian People, Breast Neoplasms chemistry, Chemical and Drug Induced Liver Injury etiology, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Hypokalemia chemically induced, Japan, Maximum Tolerated Dose, Maytansine administration & dosage, Maytansine adverse effects, Maytansine blood, Maytansine pharmacokinetics, Middle Aged, Severity of Illness Index, Thrombocytopenia chemically induced, Trastuzumab, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized pharmacokinetics, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacokinetics, Biomarkers, Tumor analysis, Breast Neoplasms blood, Breast Neoplasms drug therapy, Maytansine analogs & derivatives, Receptor, ErbB-2 analysis
- Abstract
Objective: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clinical activity in human epidermal growth factor receptor 2-positive metastatic breast cancer patients. This study evaluated the maximum tolerated dose, toxicity and pharmacokinetics of trastuzumab emtansine in Japanese breast cancer patients., Methods: Inoperable advanced or recurrent human epidermal growth factor receptor 2-positive breast cancer patients were administered trastuzumab emtansine intravenously at a dose of 1.8, 2.4 or 3.6 mg/kg every 3 weeks. The maximum tolerated dose was estimated using the continual reassessment method., Results: This study enrolled 10 patients who were administered trastuzumab emtansine for a median of seven cycles. The dose-limiting toxicity was Grade 3 elevation of aspartate aminotransferase/alanine aminotransferase at the 2.4 mg/kg dose level. The maximum tolerated dose was estimated to be 3.6 mg/kg because at the point when dose-limiting toxicity was evaluable in 10 patients, the probability of dose-limiting toxicity estimated using the continual reassessment method was closest to 25% at a dose of 3.6 mg/kg and this was unchanged by the results for patients enrolled after that. The most frequent adverse events were nausea, arthralgia, fever, fatigue and decreased appetite. Adverse events were generally tolerable. The maximum concentration and area under the concentration-time curve increased linearly with the dose., Conclusions: Trastuzumab emtansine up to 3.6 mg/kg was well tolerated by Japanese breast cancer patients. Although thrombocytopenia and hepatotoxicity tended to be more severe than was seen in Western patients in previous trastuzumab emtansine trials, those adverse events recovered without special supportive treatment., (© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
30. Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer.
- Author
-
Yagishita S, Horinouchi H, Yorozu T, Kitazono S, Mizugaki H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Mori T, Tsuta K, Sumi M, and Tamura T
- Subjects
- Autopsy, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Fatal Outcome, Female, Heart Neoplasms etiology, Humans, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Middle Aged, Bone Neoplasms etiology, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy adverse effects, Lung Neoplasms therapy, Neoplasms, Second Primary, Osteosarcoma etiology
- Abstract
A 53-year-old female patient was admitted with pain and a progressively enlarging mass in the right upper chest. Chest computed tomography revealed a mass lesion in the region of the right upper ribs. Ten years prior to this admission, the patient had undergone right lobectomy for lung adenocarcinoma. One year after the surgery, follow-up computed tomography had revealed tumor recurrence in the mediastinal and supraclavicular lymph nodes, and the patient had been treated by chemoradiotherapy. Thereafter, regular follow-up had revealed no evidence of recurrence of the non-small-cell lung cancer. Histopathological findings revealed proliferation of spindle-shaped malignant tumor cells in a background of osteoid, consistent with the diagnosis of osteosarcoma. The location of the tumor was consistent with the radiation field. Based on the clinicopathological findings, the patient was diagnosed as having secondary osteosarcoma occurring as a result of the chemoradiotherapy administered previously for the recurrent non-small-cell lung cancer. Unfortunately, the patient died of rapid progression of the osteosarcoma within a week of admission to the hospital. The autopsy revealed contiguous invasion by the tumor of the heart, with massive thrombus formation. The peripheral pulmonary arteries were diffusely occluded by metastatic tumors. Our case serves to highlight the risk of development of secondary sarcoma as a life-threatening late complication after chemoradiotherapy for locally advanced non-small-cell lung cancer, even after complete cure of the primary tumor.
- Published
- 2014
- Full Text
- View/download PDF
31. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
- Author
-
Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, and Tamura T
- Subjects
- Adenocarcinoma pathology, ErbB Receptors metabolism, Erlotinib Hydrochloride, Female, Gefitinib, Humans, Lung Neoplasms pathology, Meningeal Carcinomatosis secondary, Middle Aged, Antineoplastic Agents adverse effects, Lung Diseases, Interstitial chemically induced, Meningeal Carcinomatosis drug therapy, Protein Kinase Inhibitors therapeutic use, Quinazolines adverse effects, Quinazolines therapeutic use
- Abstract
We report the case of a 49-year-old non-smoking Japanese woman with backache and difficulty in walking. She was diagnosed as having advanced lung adenocarcinoma, and an epithelial growth factor receptor mutation (in-frame deletions in exon 19) was found. After radiation therapy of bone metastases with spinal cord compression and brain metastases, gefitinib was administered. On day 2, she developed acute interstitial lung disease. Gefitinib therapy was discontinued and treatment with high-dose steroid therapy improved the interstitial lung disease. Cisplatin plus pemetrexed was initiated as second-line chemotherapy, but she was hospitalized again for leptomeningeal carcinomatosis. Considering the poor prognosis of leptomeningeal carcinomatosis, we decided that erlotinib was our only choice of treatment. As a third-line treatment, erlotinib was administered after informing the patient about the high risk of interstitial lung disease. Neurological symptoms were improved within a week and interstitial lung disease did not recur. The patient has received erlotinib successfully for 18 months without the recurrence of leptomeningeal carcinomatosis. Erlotinib rechallenge after gefitinib-induced interstitial lung disease must be carefully chosen based on the balance of a patient's risk and benefit.
- Published
- 2013
- Full Text
- View/download PDF
32. Prognostic factors in young Japanese women with breast cancer: prognostic value of age at diagnosis.
- Author
-
Yoshida M, Shimizu C, Fukutomi T, Tsuda H, Kinoshita T, Akashi-Tanaka S, Ando M, Hojo T, and Fujiwara Y
- Subjects
- Adult, Age Factors, Breast Neoplasms pathology, Disease-Free Survival, Female, Humans, Japan epidemiology, Multivariate Analysis, Premenopause, Prognosis, Risk Factors, Survival Rate, Breast Neoplasms diagnosis, Breast Neoplasms mortality
- Abstract
Objective: The primary objective of this study was to verify whether breast cancer patients aged <35 at diagnosis have poorer prognoses than those aged 35-39, in other words, to identify the prognostic value of age in younger premenopausal patients under 40 years old. The secondary objective was to assess prognostic factors specific for younger premenopausal patients., Methods: We identified 242 consecutive patients who were diagnosed with stage I-III breast cancer before the age of 40 and underwent surgery between 1990 and 2004. We compared disease-free survival and overall survival in patients aged <35 years and those aged 35-39 years, and evaluated clinicopathological factors associated with disease-free survival or overall survival in each age group and in all patients under the age of 40., Results: Ninety-nine (41%) patients were younger than 35 years and 143 (59%) were between 35 and 39 years. No significant difference in disease-free survival or overall survival was found between the two groups. In our cohort of patients under the age of 40, the independent factors associated with poor disease-free survival and overall survival included positive axillary lymph nodes and triple-negative status, but not age at diagnosis. Adverse prognostic factors also did not differ considerably between the two age groups., Conclusions: Age at diagnosis was not an independent prognostic factor in our study. Our findings suggest that other clinicopathological features rather than age should be used to determine individualized treatment courses for breast cancer patients younger than 40 years.
- Published
- 2011
- Full Text
- View/download PDF
33. De-identification procedure and sample quality of the post-clinical test samples at the bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo.
- Author
-
Furuta K, Yokozawa K, Takada T, and Fujiwara Y
- Subjects
- Cancer Care Facilities, Humans, Quality Control, Tokyo, Biological Specimen Banks standards, Confidentiality, Neoplasms, Specimen Handling
- Abstract
We established our bio-repository in October 2002. One of the unique aspects of our bio-repository is that it is based on post-clinical test samples. Although the post-clinical test sample-based storage is beneficial because ample clinical information is available for each sample and samples are to be refreshed regularly, many bio-bankers are hesitant to store them because of the possible problems of de-identification procedures and sample quality. Currently, we have two different types of sample, not de-identified status and de-identified status. Most of the samples for storage are not de-identified status. A portion of the samples are transferred to new tubes before and after being frozen, without clinical patient identifications and the status is de-identified. This tube transfer is the only de-identification procedure in our bio-repository so far. After a procedure of de-identification, these samples are stored. The de-identified samples are collected under various project-based schemes. The quality standards of our samples are established by two factors: pre-analytical quality control efforts, and record keeping of sample history by sample tracking system. All the samples have been phlebotomized under strict control of pre-analytical requirements. By record keeping of sample history with the sample tracking system, we can tell the exact temperature and elapsed time in various situations since the phlebotomy procedure or on arrival at the clinical laboratory. In this article, we will disclose how we have dealt with the de-identification procedure and sample quality.
- Published
- 2011
- Full Text
- View/download PDF
34. Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: case report.
- Author
-
Iwasa S, Ando M, Ono M, Hirata T, Yunokawa M, Nakano E, Yonemori K, Kouno T, Shimizu C, Tamura K, Katsumata N, and Fujiwara Y
- Subjects
- Adult, Biomarkers, Tumor analysis, Bleomycin administration & dosage, Cisplatin administration & dosage, Etoposide administration & dosage, Fluorodeoxyglucose F18, Humans, Male, Mediastinal Neoplasms chemistry, Mediastinal Neoplasms pathology, Neoplasm Recurrence, Local chemistry, Neoplasm Recurrence, Local diagnosis, Positron-Emission Tomography, Radiopharmaceuticals, Seminoma chemistry, Seminoma pathology, Tomography, X-Ray Computed, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Mediastinal Neoplasms drug therapy, Neoplasm Recurrence, Local etiology, Seminoma drug therapy
- Abstract
This case report details a relapse with malignant transformation after the completion of bleomycin, etoposide and cisplatin chemotherapy for primary mediastinal seminoma, although the residual mass after chemotherapy was <3 cm in size and did not display an increased uptake of fluorodeoxyglucose when examined using positron emission tomography.
- Published
- 2009
- Full Text
- View/download PDF
35. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
- Author
-
Fujiwara Y, Sekine I, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Simmyo Y, Fukui T, Yamada K, and Tamura T
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents toxicity, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic toxicity, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Camptothecin toxicity, Cisplatin administration & dosage, Cisplatin adverse effects, Diarrhea chemically induced, Female, Humans, Irinotecan, Male, Middle Aged, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols toxicity, Bilirubin blood, Lung Neoplasms drug therapy, Neutropenia chemically induced
- Abstract
Objective: To clarify the association between pre-treatment total bilirubin (PTB) level and severe toxicity in patients receiving cisplatin and irinotecan., Methods: We analyzed retrospectively the relationships of grade 4 neutropenia or grade 3-4 diarrhea and clinical variables including PTB and pre-treatment neutrophil counts (PNC) using a logistic regression model., Results: One hundred and twenty-seven patients (93 men, 34 women; median age: 61 years; range: 24-74 years) received cisplatin (60 or 80 mg/m2) on day 1 and irinotecan (60 mg/m2) on days 1 and 8 every 3 weeks or on days 1, 8 and 15 every 4 weeks. Grade 4 neutropenia occurred in 29 patients (23%) and grade 3-4 diarrhea occurred in 13 patients (10%). Grade 4 neutropenia was associated with a higher PTB level (odds ratio: 4.9; 95% confidence interval: 1.4-17.7), a higher cisplatin dose (2.8, 1.0-7.8) and a lower PNC (1.5, 1.0-2.3). Grade 3-4 diarrhea was associated with liver metastasis (11.2, 2.2-57.4), a higher cisplatin dose (5.0, 1.2-21.3) and a lower PNC (2.0, 1.1-3.6)., Conclusions: PTB level was associated with the severity of neutropenia caused by cisplatin and irinotecan.
- Published
- 2007
- Full Text
- View/download PDF
36. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer.
- Author
-
Shimizu C, Ando M, Kouno T, Katsumata N, and Fujiwara Y
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms surgery, Chemotherapy, Adjuvant, Female, Humans, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Medical Oncology trends
- Abstract
The multi-disciplinary approach, including surgery, chemotherapy, endocrine therapy and radiation therapy, has become the standard treatment for primary breast cancer patients. The indication of pre-operative chemotherapy has been extended to women with potentially operable breast cancer based on the results of large randomized studies and has become an attractive option that extends the chance of breast conservation. The clinical and pathological responses to pre-operative chemotherapy correlates with long-term outcome. The anthracycline-containing regimen is now considered the standard. Sequential administration of non-cross-resistant drugs, namely taxanes, improves local tumor response but its long-term benefit has been controversial. Prediction of response to pre-operative chemotherapy still remains a challenge. Identification of useful predictive markers and development of molecular-targeted drugs is the key to individualized therapy in the future.
- Published
- 2007
- Full Text
- View/download PDF
37. Prognostic factors in small cell lung cancer: multivariate analysis in the National Cancer Center Hospital (Japan).
- Author
-
Shinkai T, Sakurai M, Eguchi K, Sasaki Y, Tamura T, Fujiwara Y, Fukuda M, Yamada K, Kojima A, and Sasaki S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell therapy, Combined Modality Therapy, Female, Humans, Lung Neoplasms therapy, Male, Middle Aged, Prognosis, Retrospective Studies, Sex Factors, Carcinoma, Small Cell mortality, Lung Neoplasms mortality
- Abstract
Consecutive series involving 172 patients with small cell lung cancer were analyzed retrospectively using eight pretreatment and two treatment-related prognostic factors in respect of their influence on survival. All the patients received chemotherapy with or without chest irradiation, according to phase II or phase III trial protocols of the National Cancer Center Hospital, Tokyo, from 1970 to 1987. The influence on survival of the various factors was investigated using univariate methods and Cox's proportional hazards model. In patients who survived for more than one year, a performance status of 0-1, limited disease, an age greater than 60 years, the absence of liver metastasis, radiotherapy to primary site and response to chemotherapy were determined by univariate analysis to be favorable prognostic factors. By multivariate analysis, performance status (P = 0.005), age (P = 0.026) and response to induction chemotherapy (P = 0.0001) proved to be valuable prognostic survival factors. The extent of disease which had been considered one of the most significant prognostic factors, was shown not to be a significant independent variable by multivariate analysis. Staging procedures may influence the prognostic analysis. Although classifying the limited or extensive stage of disease is still recommended, the current staging system lacks stringency and may not, in fact, reflect the tumor burden accurately. A simpler and meaningful staging system needs to adopted universally in order to continue the build-up of data for comparison from all institutions.
- Published
- 1989
38. Phase II study of carboplatin in non-small cell lung cancer.
- Author
-
Tamura T, Shinkai T, Eguchi K, Sasaki Y, Fujiwara Y, Fukuda M, Ohe Y, Nakagawa K, Minato K, and Saijo N
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Carboplatin, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung secondary, Drug Evaluation, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Organoplatinum Compounds adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Organoplatinum Compounds therapeutic use
- Abstract
Forty four patients with advanced non-small cell lung cancer (NSCLC) were treated with carboplatin (CBDCA; cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) at a dose of 400-450 mg/m2 intravenously every four weeks in a phase II study. Forty three patients were evaluated for response and toxicity. Two patients achieved responses resulting in an overall response rate of 4.7% (95% confidence limits: 0.6-15.8%); one of these had not been treated previously and the other had been treated previously with vinblastine. The durations of their responses were 5 and 7 months, respectively. The response rate in 28 previously untreated patients was 3.6% (1/28; 95% confidence limits: 0.1-18.3%). Myelosuppression was the most commonly found toxicity, and thrombocytopenia especially was dose-limiting. Thrombocytopenia (less than 75,000/mm3) was observed in 12 patients (28%). Leukopenia (less than 3,000/mm3) was observed in 14 patients (33%). No serious infection or bleeding occurred, however. Treatment with 400-450 mg CBDCA/m2 was well tolerated in the good risk patients in this study. Mild to moderate emesis was observed in 28 patients (65%). No renal toxicity, neurotoxicity or ototoxicity was seen. It was demonstrated that CBDCA had little efficacy in NSCLC at the dose and schedule given in the present study.
- Published
- 1989
39. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
- Author
-
Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Fujiwara Y, Mae M, Fukuda M, Ohe Y, and Sasaki S
- Subjects
- Adult, Aged, Antiemetics adverse effects, Antiemetics therapeutic use, Cisplatin therapeutic use, Dexamethasone adverse effects, Dexamethasone therapeutic use, Drug Therapy, Combination, Female, Humans, Infusions, Intravenous, Lung Neoplasms drug therapy, Male, Metoclopramide adverse effects, Metoclopramide therapeutic use, Middle Aged, Random Allocation, Antiemetics administration & dosage, Cisplatin adverse effects, Dexamethasone administration & dosage, Metoclopramide administration & dosage, Vomiting drug therapy
- Abstract
Forty-two patients with advanced lung cancer undergoing chemotherapy containing cisplatin (80 mg/m2) were submitted to a randomized controlled trial to evaluate the effect of the combination of metoclopramide and dexamethasone for the treatment of delayed cisplatin-induced emesis occurring more than 24 hours after cisplatin administration. All patients received intravenously (i.v.) high-dose metoclopramide and dexamethasone on the day of cisplatin treatment. Excellent emetic control (no emesis during the 24 hours following cisplatin administration) was achieved in 30 out of 41 patients (73%) with this combination. Patients treated i.v. with metoclopramide and dexamethasone on days 2-7 experienced less delayed emesis, nausea and anorexia compared to those treated with a placebo (delayed emesis, 25 vs 50%, respectively, P = 0.105; more than four days of nausea, 10 vs 35%, respectively, P = 0.059; less than three days of anorexia, 80 vs 50%, respectively, P = 0.048). Although the results of the study showed no statistically significant advantage with the combination of i.v. metoclopramide and dexamethasone for patients treated with cisplatin, in view of the short duration of anorexia and the marginal reduction in nausea. Female patients tended to have more emetic episodes and extrapyramidal side effects (except akathisia) than male patients, but the differences were not statistically significant except for acute emesis (P less than 0.005).
- Published
- 1989
40. A case of adenocarcinoma of the lung which was successfully treated by chemotherapy with patient survival without recurrence for more than three years.
- Author
-
Akiba T, Saijo N, Miyamoto K, Sakurai M, Tamura T, Sasaki Y, Eguchi K, Shinkai T, Uei Y, and Fujiwara Y
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma pathology, Cisplatin administration & dosage, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Podophyllotoxin administration & dosage, Smoking, Vincristine administration & dosage, Vindesine administration & dosage, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lung Neoplasms drug therapy, Neoplasm Recurrence, Local prevention & control
- Abstract
A 63-year-old man was admitted to the National Cancer Center Hospital on December 20, 1983 for a close examination of the abnormal shadows found in chest roentgenograms. Chest radiographs showed a massive right pleural effusion, a large tumor in the right hilar region and swelling of the left hilar nodes. Transcutaneous needle biopsy revealed the tumor's cytological type to be adenocarcinoma. The clinical stage was considered to be T3N2M1 (American joint committee (AJC) stage III M1), and his performance status was 4, so he was given etoposide (VP-16) alone as the initial chemotherapy treatment. He showed a partial response upon two courses of VP-16 therapy. Subsequently, one course of cisplatin (80 mg/m2) + vindesine (3.3 mg/m2), two courses of VP-16 (80 mg/m2 D1-4), five courses of cyclophosphamide (80 mg/m2) + adriamycin (50 mg/m2) + vincristine (1.4 mg/m2) and two courses of VP-16 (100 mg/m2 D1, 3, 5) were administered sequentially until May 31, 1985. No radiation therapy was given and, up to March 31, 1987, no sign of recurrence had been observed.
- Published
- 1987
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.